Alkermes plc Q4 2025 Earnings Call Summary [Yahoo! Finance]
Alkermes plc - Ordinary Shares (ALKS)
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-irhome
Company Research
Source: Yahoo! Finance
Alkermes plc Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Portfolio Evolution Management characterizes 2025 as a pivotal year, transitioning from a royalty-based technology company to a proprietary products business focused on neuroscience and sleep medicine. The acquisition of Avadel is described as a strategic accelerator, providing an immediate revenue stream via LUMRIZE and a commercial platform for future orexin launches. Performance in the psychiatry franchise was attributed to a 2025 sales force expansion, which increased call frequency and prescriber breadth for LYBALVI and ARISTADA. Management views the orexin 2 receptor agonist portfolio as a new growth vertical, with elixorexant positioned as a potential blockbuster to advance the standard of care in hypersomnia. Operational efficiencies following the sale of the Athlone manufacturing site in 2024 contributed to improved cost of goods sold in the current period. The company is pivoting it
Show less
Read more
Impact Snapshot
Event Time:
ALKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALKS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALKS alerts
High impacting Alkermes plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ALKS
News
- Alkermes (ALKS) had its price target raised by Wells Fargo & Company from $37.00 to $43.00. They now have an "overweight" rating on the stock.MarketBeat
- Alkermes (ALKS) had its price target lowered by Royal Bank Of Canada from $47.00 to $45.00. They now have an "outperform" rating on the stock.MarketBeat
- Alkermes (ALKS) had its "neutral" rating reaffirmed by HC Wainwright.MarketBeat
- Alkermes: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026 [Yahoo! Finance]Yahoo! Finance
ALKS
Earnings
- 2/25/26 - Miss
ALKS
Sec Filings
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- 3/4/26 - Form 4
- ALKS's page on the SEC website